MCID: OVR012
MIFTS: 48

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 55 6 15 73
Cystadenoma, Serous 73
Serous Cystadenoma 12
Cystadenoma Serous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 50 C7978

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to cystadenocarcinoma and serous cystadenocarcinoma. An important gene associated with Ovarian Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 cystadenocarcinoma 30.0 FBXW7 HRAS MUC16 PGR PIK3CA PPP2R1A
2 serous cystadenocarcinoma 29.4 B2M FBXW7 HRAS MUC16 PATL2 PGR
3 ovarian cancer 27.5 BCL2 BRAF FSHR MUC16 PGR PIK3CA
4 pancreatic serous cystadenoma 12.6
5 giant congenital nevus 11.0 HRAS NRAS
6 rare adenocarcinoma of the breast 10.9 PIK3CA TP53
7 nevus of ota 10.9 BRAF TP53
8 adult hepatocellular carcinoma 10.9 PIK3CA TP53
9 malignant spiradenoma 10.9 PIK3CA TP53
10 apocrine adenoma 10.8 HRAS PIK3CA
11 endometrium carcinoma in situ 10.8 PGR TP53
12 lung adenoid cystic carcinoma 10.8 FBXW7 HRAS PIK3CA
13 erdheim-chester disease 10.8 BRAF NRAS PIK3CA
14 nevus, epidermal 10.8 HRAS NRAS PIK3CA
15 epithelial-myoepithelial carcinoma 10.8 FBXW7 HRAS TP53
16 acneiform dermatitis 10.8 HRAS NRAS PIK3CA
17 vestibular gland benign neoplasm 10.8 PGR TP53
18 prostate adenoid cystic carcinoma 10.8 HRAS LRRC56 PIK3CA
19 bartholin's gland adenoma 10.8 PGR TP53
20 brain stem glioma 10.8 BRAF PIK3CA TP53
21 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.8 PIK3CA PPP2R1A TP53
22 ovarian cancer 1 10.8 HRAS PIK3CA TP53
23 bladder squamous cell carcinoma 10.8 BRAF PIK3CA TP53
24 integumentary system cancer 10.8 HRAS NRAS TP53
25 anaplastic thyroid cancer 10.7 BRAF PIK3CA TP53
26 benign struma ovarii 10.7 HRAS NRAS
27 ovary adenocarcinoma 10.7 HRAS TP53 ZNF217
28 breast squamous cell carcinoma 10.7 PGR PIK3CA TP53
29 schimmelpenning-feuerstein-mims syndrome 10.7 HRAS NRAS
30 pulmonic stenosis 10.7 BRAF HRAS LRRC56
31 melanoma, cutaneous malignant 1 10.7 HRAS NRAS TP53
32 hyperplastic polyposis syndrome 10.7 BRAF TP53
33 respiratory system cancer 10.7 HRAS PIK3CA TP53
34 meningeal melanomatosis 10.6 B2M HRAS NRAS TP53
35 colorectal adenocarcinoma 10.6 BRAF HRAS TP53
36 uterine body mixed cancer 10.6 PGR PPP2R1A TP53
37 adrenocortical carcinoma, hereditary 10.6 BRAF NRAS PIK3CA TP53
38 suppression of tumorigenicity 12 10.6 BRAF HRAS PIK3CA TP53
39 ovarian cystadenocarcinoma 10.6 HRAS UBE4A ZNF217
40 pilocytic astrocytoma 10.6 BRAF HRAS PIK3CA TP53
41 estrogen-receptor positive breast cancer 10.6 PGR PIK3CA TP53
42 spitz nevus 10.6 BRAF HRAS LRRC56 TP53
43 gastrointestinal system cancer 10.6 HRAS PIK3CA TP53
44 ovarian clear cell carcinoma 10.5 PIK3CA PPP2R1A TP53 ZNF217
45 thyroid cancer, nonmedullary, 2 10.5 BRAF HRAS NRAS PIK3CA
46 cervical carcinosarcoma 10.5 BCL2 PGR TP53
47 ovary epithelial cancer 10.5 HRAS PGR PIK3CA TP53
48 lung squamous cell carcinoma 10.5 BRAF HRAS PIK3CA TP53
49 cell type cancer 10.5 HRAS NRAS PGR TP53
50 female reproductive endometrioid cancer 10.4 PGR TP53

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 9.96 USP2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.96 USP14
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.96 BCL2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.96 BCL2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.96 USP2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 9.96 BCL2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.96 BCL2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.96 USP2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.96 USP2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.96 HRAS
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.96 BCL2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.96 HRAS USP14 USP2 BCL2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.96 BCL2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.96 HRAS BCL2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.96 HRAS USP14
16 Increased cell death HMECs cells GR00103-A-0 9.1 FBXW7 PGR PIK3CA PPP2R1A TP53 ZNF217

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 NANOG PIK3CA NRAS PGR USP14 USP2
2 behavior/neurological MP:0005386 10.3 PGR HRAS PIK3CA NRAS PPP2R1A YAP1
3 cardiovascular system MP:0005385 10.29 HRAS PIK3CA NRAS TP53 PGR USP2
4 endocrine/exocrine gland MP:0005379 10.21 HRAS PIK3CA NRAS TP53 PGR USP2
5 homeostasis/metabolism MP:0005376 10.21 PGR HRAS PIK3CA NRAS PPP2R1A TP53
6 growth/size/body region MP:0005378 10.18 HRAS PIK3CA NRAS PPP2R1A YAP1 TP53
7 embryo MP:0005380 10.11 PGR NANOG PIK3CA NRAS YAP1 TP53
8 integument MP:0010771 10.1 PIK3CA NRAS TP53 PGR USP14 YAP1
9 mortality/aging MP:0010768 10.1 PGR HRAS NANOG PIK3CA NRAS PPP2R1A
10 digestive/alimentary MP:0005381 10.08 HRAS NRAS YAP1 TP53 FBXW7 BCL2
11 neoplasm MP:0002006 9.93 PIK3CA NRAS PPP2R1A TP53 PGR YAP1
12 no phenotypic analysis MP:0003012 9.5 PGR HRAS NANOG PIK3CA NRAS TP53
13 reproductive system MP:0005389 9.28 PGR PIK3CA TP53 USP14 USP2 B2M

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
8 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
9 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
10 Antimitotic Agents Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
12 Alkylating Agents Phase 3,Phase 2,Phase 1
13 Mitogens Phase 3,Phase 1
14 Angiogenesis Inhibitors Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 1
16 Endothelial Growth Factors Phase 3,Phase 1
17 Immunoglobulin G Phase 3,Phase 1
18 Antibodies Phase 3,Phase 1
19 Immunoglobulins Phase 3,Phase 1
20 Antibodies, Monoclonal Phase 3,Phase 1
21 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
24 Analgesics Phase 3,Phase 1
25 Micronutrients Phase 3,Not Applicable
26 Trace Elements Phase 3,Not Applicable
27 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
28 Vitamin B Complex Phase 3,Not Applicable
29 Vitamins Phase 3,Not Applicable
30 Folate Nutraceutical Phase 3,Not Applicable
31 Vitamin B9 Nutraceutical Phase 3,Not Applicable
32
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
33
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
34
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
35
Docetaxel Approved, Investigational Phase 1, Phase 2,Phase 2 114977-28-5 148124
36
Belinostat Approved, Investigational Phase 2 866323-14-0
37
Metformin Approved Phase 2,Phase 1 657-24-9 14219 4091
38
Gemcitabine Approved Phase 2 95058-81-4 60750
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
41
Everolimus Approved Phase 2 159351-69-6 6442177
42
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
43
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
44
Doxil Approved June 1999 Phase 2,Phase 1 31703
45 Anti-Bacterial Agents Phase 2,Phase 1
46 Antibiotics, Antitubercular Phase 2,Phase 1
47
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
48 topoisomerase I inhibitors Phase 2,Phase 1
49 Adjuvants, Immunologic Phase 2,Phase 1
50 Histone Deacetylase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
6 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
7 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
8 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
9 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
10 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
11 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
12 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
13 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
14 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
15 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
16 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
17 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
18 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
19 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
20 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
21 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
22 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
23 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
24 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
25 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
26 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
27 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
28 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib
29 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
30 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
31 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
32 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
33 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
34 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
35 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
36 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
37 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
38 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
39 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
40 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
41 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
42 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
43 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
44 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
45 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
46 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Recruiting NCT02142803 Phase 1 Sapanisertib
47 EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT01489371 Phase 1 Pegylated Liposomal Doxorubicin Hydrochloride
48 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Active, not recruiting NCT00357448 Phase 1
49 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
50 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00408590 Phase 1

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

41
Ovary, Endothelial, Liver, Brain, Bone, Bone Marrow

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 20)
# Title Authors Year
1
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
2
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
3
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
4
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
5
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
6
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
7
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
8
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
9
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
10
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
11
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
12
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
13
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
14
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001
15
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. ( 11516810 )
2001
16
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. ( 10968352 )
2000
17
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. ( 9506768 )
1998
18
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. ( 2314830 )
1990
19
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). ( 3165255 )
1988
20
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. ( 3598277 )
1987

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6
(show top 50) (show all 445)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
9 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
10 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
11 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
12 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
20 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
21 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
22 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
23 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
24 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
25 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
28 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
29 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
32 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
33 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
34 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
35 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
37 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
38 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
39 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
43 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
44 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
45 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
46 BRAF NM_004333.4(BRAF): c.1741A> C (p.Asn581His) single nucleotide variant Likely pathogenic rs180177040 GRCh37 Chromosome 7, 140453987: 140453987
47 BRAF NM_004333.4(BRAF): c.1741A> C (p.Asn581His) single nucleotide variant Likely pathogenic rs180177040 GRCh38 Chromosome 7, 140754187: 140754187
48 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
49 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh38 Chromosome 4, 152326137: 152326137
50 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 NCBI36 Chromosome 4, 153466739: 153466739

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 B2M BCL2 BRAF FBXW7 HRAS MUC16
2
Show member pathways
13.49 B2M FBXW7 HRAS NRAS PIK3CA PPP2R1A
3
Show member pathways
13.29 B2M BCL2 BRAF HRAS NANOG NRAS
4
Show member pathways
13.06 BCL2 HRAS NRAS PGR PIK3CA PPP2R1A
5
Show member pathways
13.01 BCL2 HRAS NRAS PIK3CA PPP2R1A TP53
6
Show member pathways
12.89 BCL2 BRAF HRAS NRAS PIK3CA TP53
7 12.84 BCL2 BRAF HRAS NRAS PIK3CA TP53
8
Show member pathways
12.83 BCL2 HRAS NRAS PIK3CA TP53
9
Show member pathways
12.75 HRAS NRAS PIK3CA PPP2R1A TP53
10
Show member pathways
12.74 BCL2 BRAF HRAS NRAS PIK3CA TP53
11
Show member pathways
12.7 BRAF HRAS NRAS PPP2R1A TP53
12
Show member pathways
12.68 BCL2 BRAF HRAS NRAS PIK3CA TP53
13
Show member pathways
12.6 BCL2 HRAS NRAS PIK3CA TP53
14
Show member pathways
12.59 BRAF HRAS NRAS PIK3CA PPP2R1A
15
Show member pathways
12.58 BCL2 BRAF HRAS NRAS PGR PIK3CA
16
Show member pathways
12.56 BRAF HRAS NRAS PIK3CA TP53
17 12.54 BCL2 HRAS NRAS PIK3CA TP53
18
Show member pathways
12.51 BRAF HRAS NRAS PIK3CA TP53
19
Show member pathways
12.5 BCL2 HRAS NRAS PIK3CA
20
Show member pathways
12.48 BRAF HRAS NRAS PIK3CA TP53
21
Show member pathways
12.47 BCL2 HRAS NRAS PIK3CA TP53 YAP1
22
Show member pathways
12.46 BCL2 BRAF HRAS NRAS
23
Show member pathways
12.45 HRAS PIK3CA PPP2R1A TP53
24
Show member pathways
12.44 BCL2 BRAF HRAS NRAS
25 12.44 HRAS NRAS PIK3CA TP53
26
Show member pathways
12.43 BCL2 HRAS NRAS PIK3CA TP53
27
Show member pathways
12.4 BRAF HRAS NRAS PIK3CA
28
Show member pathways
12.37 BRAF PGR PIK3CA PPP2R1A
29 12.32 HRAS NRAS PIK3CA TP53
30
Show member pathways
12.24 BRAF HRAS NRAS TP53
31
Show member pathways
12.23 BRAF HRAS NRAS PIK3CA PPP2R1A
32 12.2 HRAS NRAS PIK3CA TP53
33
Show member pathways
12.18 BRAF HRAS NRAS TP53
34
Show member pathways
12.17 HRAS NRAS PIK3CA TP53
35
Show member pathways
12.12 BCL2 HRAS NRAS PIK3CA PPP2R1A
36 12.12 HRAS NANOG NRAS PIK3CA
37 12.12 BCL2 HRAS NRAS PIK3CA TP53
38
Show member pathways
12.11 BRAF HRAS NRAS PIK3CA
39 12.07 BCL2 HRAS NRAS PIK3CA
40
Show member pathways
12.04 BCL2 HRAS NRAS PPP2R1A
41
Show member pathways
12.04 BRAF HRAS NRAS PIK3CA TP53
42 12 HRAS NRAS PIK3CA TP53
43 11.98 BRAF HRAS NRAS PPP2R1A
44 11.96 BRAF HRAS NRAS TP53
45 11.94 BRAF HRAS NANOG NRAS PIK3CA TP53
46 11.93 BCL2 BRAF HRAS TP53
47 11.89 BCL2 HRAS NRAS PIK3CA
48 11.88 BCL2 PIK3CA TP53
49
Show member pathways
11.88 HRAS NRAS PIK3CA
50
Show member pathways
11.86 HRAS NRAS PIK3CA

GO Terms for Ovarian Serous Cystadenocarcinoma

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 BCL2 BRAF FBXW7 HRAS NANOG PATL2

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 BRAF FBXW7 FSHR HRAS
2 cell proliferation GO:0008283 9.72 BCL2 HRAS NANOG TP53 YAP1
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.7 BCL2 BRAF PIK3CA
4 Ras protein signal transduction GO:0007265 9.65 HRAS NRAS TP53
5 somatic stem cell population maintenance GO:0035019 9.58 BRAF NANOG YAP1
6 negative regulation of neuron apoptotic process GO:0043524 9.56 BCL2 BRAF HRAS PIK3CA
7 regulation of mitochondrial membrane permeability GO:0046902 9.54 BCL2 TP53
8 epidermal growth factor receptor signaling pathway GO:0007173 9.54 HRAS NRAS PIK3CA
9 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.49 FSHR YAP1
10 progesterone receptor signaling pathway GO:0050847 9.46 PGR YAP1
11 circadian behavior GO:0048512 9.43 TP53 USP2
12 ERBB2 signaling pathway GO:0038128 9.33 HRAS NRAS PIK3CA
13 cell aging GO:0007569 9.13 BCL2 HRAS TP53
14 cellular response to gamma radiation GO:0071480 8.8 HRAS TP53 YAP1

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.65 BCL2 BRAF PPP2R1A TP53 YAP1
2 protein binding GO:0005515 9.6 B2M BCL2 BRAF FBXW7 FSHR HRAS
3 identical protein binding GO:0042802 9.5 B2M BCL2 BRAF FBXW7 PGR TP53
4 transcription regulatory region DNA binding GO:0044212 9.46 NANOG TP53 YAP1 ZNF217

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....